Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)

NCT06403267 is registered in ClinicalTrials.gov with NoNO Inc. as lead sponsor.

NCT NCT06403267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06403267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)
Lead sponsor
NoNO Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
October 2, 2024
Completion date
December 31, 2026
Enrollment
600 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke